Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

EpiCor’s ability to favorably shift CD4/CD8 cells suggests an application worth considering when dealing with a viral burden on the body. Is this correct?

April 26, 2017ability application CD4 cells epicor favorably shift suggests worth

0

Posted

EpiCor’s ability to favorably shift CD4/CD8 cells suggests an application worth considering when dealing with a viral burden on the body. Is this correct?

1 Answer

0

Posted

A. Yes. The improved CD4/CD8 ratio is precisely what is desired for those dealing with a viral burden, as this ratio is often disrupted in this group. There is no research specifically done in this area yet. However, it certainly seems as if EpiCor would be a tool worth strong consideration.